8 drug(s) with this reaction
9,844 total reports
Neutropenia has been reported as an adverse reaction across 8 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 9,844 adverse event reports mention neutropenia in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with neutropenia, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have neutropenia listed in their FDA adverse event reports, sorted by report count:
In addition to neutropenia, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
8 drug(s) manufactured by Amgen Inc have neutropenia listed in their FDA adverse event reports: FILGRASTIM, PEGFILGRASTIM, DENOSUMAB, PANITUMUMAB, DARBEPOETIN ALFA, and others.
There are a combined 9,844 reports of neutropenia across 8 Amgen Inc drug(s) in the FDA adverse event database.